Clinical Trial Update: Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial combining gp96-Ig vaccine, theophylline, and oxygen for advanced, relapsed or metastatic non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Theophylline (Theophylline)
• gp96-Ig vaccine

Snippet

Sponsor: Eckhard Podack | Conditions: Non-Small Cell Lung Cancer, Non-small-cell Lung Carcinoma | Phase 1 | Status: WITHDRAWN